BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge

dc.creatorRamírez, Laura
dc.creatorIborra, Salvador
dc.creatorCortés, Jimena
dc.creatorBonay, Pedro
dc.creatorAlonso, Carlos
dc.creatorBarral Netto, Manoel
dc.creatorSoto, Manuel
dc.date2014-02-27T18:59:46Z
dc.date2014-02-27T18:59:46Z
dc.date2010
dc.date.accessioned2023-09-26T20:28:11Z
dc.date.available2023-09-26T20:28:11Z
dc.identifierRAMÍREZ, L. et al. BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge. Journal of Biomedicine and Biotechnology, p. 1-10, 2010.
dc.identifier1110-7251
dc.identifier10.1155/2010/181690
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/7370
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8857595
dc.descriptionLeishmaniasis is an increasing public health problem and effective vaccines are not currently available. We have previously demonstrated that vaccination with ribosomal proteins extracts administered in combination of CpG oligodeoxynucleotides protects susceptible BALB/c mice against primary Leishmania major infection. Here, we evaluate the long-term immunity to secondary infection conferred by this vaccine.We show that vaccinated and infected BALB/c mice were able to control a secondary Leishmania major challenge, since no inflammation and very low number of parasites were observed in the site of reinfection. In addition, although an increment in the parasite burden was observed in the draining lymph nodes of the primary site of infection we did not detected inflammatory lesions at that site. Resistance against reinfection correlated to a predominant Th1 response against parasite antigens. Thus, cell cultures established from spleens and the draining lymph node of the secondary site of infection produced high levels of parasite specific IFN-γ in the absence of IL-4 and IL-10 cytokine production. In addition, reinfected mice showed a high IgG2a/IgG1 ratio for anti-Leishmania antibodies. Our results suggest that ribosomal vaccine, which prevents pathology in a primary challenge, in combination with parasite persistence might be effective for long term maintenance of immunity.
dc.formatapplication/pdf
dc.languageeng
dc.publisherHindawi Publishing Corporation
dc.rightsopen access
dc.subjectLeishmania major/imunologia
dc.subjectVacinas contra Leishmaniose/imunologia
dc.subjectLeishmaniose Cutânea/imunologia
dc.subjectOligodesoxirribonucleotídeos/imunologia
dc.subjectProteínas de Protozoários/imunologia
dc.subjectProteínas Ribossômicas/imunologia
dc.subjectAnimais
dc.subjectAntígenos de Protozoários/imunologia
dc.subjectCitocinas/imunologia
dc.subjectCitocinas/metabolismo
dc.subjectModelos Animais de Doenças
dc.subjectFeminino
dc.subjectVacinas contra Leishmaniose/farmacologia
dc.subjectLeishmaniose Cutânea/prevenção & controle
dc.subjectCamundongos
dc.subjectCamundongos Endogâmicos BALB C
dc.titleBALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge
dc.typeArticle


Este ítem pertenece a la siguiente institución